ArticleFrontiers in immunology2026
YWHAG overexpression correlates with an immune-desert microenvironment and poor prognosis in laryngeal squamous cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Laryngeal squamous cell carcinoma (LSCC) remains a major cause of cancer-related mortality among head and neck malignancies. The tumor immune microenvironment plays a critical role in determining disease outcome; however, the specific immune cell composition and its prognostic relevance in LSCC have not been fully elucidated. Methods: CIBERSORT was applied to bulk RNA-sequencing data from 381 TCGA-HNSCC samples to estimate the relative fractions of 22 immune cell types. LSCCs (n = 64) were selected for in-depth analyses. Consensus clustering based on immune profiles stratified patients into three clusters. Differentially expressed genes (DEGs) and pathway enrichment analyses were performed between Cluster 1 (immune-desert) and Clusters 2 & 3 (immune-active). Kaplan-Meier survival analysis was used for prognostic assessment. YWHAG protein expression was evaluated by immunohistochemistry in an independent institutional cohort of patients with LSCC (n = 23), and its correlation with clinicopathological parameters was examined. Results: Across HNSCC subsites, LSCC tumors exhibited significantly higher infiltration of naive B cells and plasma cells than tumors from other anatomical sites (Kruskal-Wallis test, adjusted Conclusions: LSCC harbors distinct immune microenvironmental subtypes. Tumors enriched for B cell- and TLS- related gene signatures demonstrate favorable outcomes, whereas immune-desert tumors with elevated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.